Connect with us

Hi, what are you looking for?

Jewish Business News

Business

Perrigo buys Crohn’s disease drug for $380 million

Perrigo is acquiring gastroenterology drug Entocort from AstraZeneca.

Joseph C. Papa - PERRIGO - PR

 

Perrigo will acquire Entocort (budesonide) capsules as well as the authorized generic capsules marketed by Par Pharmaceuticals within the US from AstraZeneca plc for $380 million.

Entocort, a gastroenterology medicine for patients with mild to moderate Crohn’s disease, has exhibited consistent revenue streams since the launch of limited generic competition in 2011.

Perrigo Chairman and CEO Joseph Papa said, “Strategically, Entocort fits well within our growing Rx portfolio and serves as yet another example of our ability to execute on our ‘Base Plus Plus Plus’ strategy. We are excited to add this margin-enhancing asset to our already robust Rx portfolio and remain committed to pursuing accretive transactions, such as this one, to continue delivering superior value for our shareholders.”

The transaction is expected to immediately exceed Perrigo’s ROIC threshold and be more than $0.35 accretive to 2016 adjusted EPS after the exclusion of estimates for intangible amortization, transaction costs and integration related expenses. The transaction is expected to close by the end of 2015, subject to customary closing conditions.

Newsletter



Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Entertainment

The Movie The Professional is what made Natalie Portman a Lolita.

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.